David A. Siegel Design Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 404,000 shares of DSGN stock, worth $1.35 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
404,000
Previous 585,000
30.94%
Holding current value
$1.35 Million
Previous $1.55 Million
5.03%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding DSGN
# of Institutions
95Shares Held
30.5MCall Options Held
100Put Options Held
100-
Sr One Capital Management, LP6.53MShares$21.9 Million8.85% of portfolio
-
Logos Global Management LP San Francisco, CA5.03MShares$16.9 Million1.89% of portfolio
-
Black Rock Inc. New York, NY2.27MShares$7.62 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY1.66MShares$5.57 Million0.08% of portfolio
-
Tang Capital Management LLC San Diego, CA1.48MShares$4.96 Million0.73% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $187M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...